Systematic Review and Meta-analysis of the Prognostic Significance of miRNAs in Melanoma Patients

Shanthi Sabarimurugan, Madhav Madurantakam Royam, Ankita Das, Shrestha Das, G. Gothandam, Rama Jayaraj

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

Background: Melanoma is the most aggressive and deadly form of skin cancer. The molecular variability involving microRNA (miRNA) expression plays a significant role in melanogenesis, which leads to poor prognostic effects in melanoma. Since there is a scarcity of comprehensive data on the prognostic role of miRNAs in melanoma patients, this study focuses on filling this knowledge gap through a systematic review and meta-analysis.

Methods: The included studies were extracted from several bibliographic databases between 2012 and 2018 using multiple keywords according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The hazard ratios (HRs) and 95% confidence intervals (CIs) for different survival endpoints were compared to the high and low expression levels of miRNAs. The mean effect size of HR values was estimated using a random-effects model of meta-analysis. Inverted funnel plot symmetry was used to assess publication bias. Subgroup analysis was carried out individually for multiple miRNAs across different studies.

Results: A total of 24 studies across eight countries were included, of which 16 studies were eligible for meta-analysis. Twenty-five miRNA expression levels were studied from 2669 melanoma patients to estimate the association between the prognostic role of miRNAs and survival outcome in these 16 studies. The overall pooled effect size (HR) for up- and downregulated miRNAs was 1.043 (95% CI 0.921–1.181; p = 0.506), indicating that the miRNA expression increased the likelihood of death in melanoma patients by 4.3%. Subgroup analysis for miRNA10b, miRNA16 and miRNA21 showed a poor prognosis. The quality assessment revealed that 16 studies were good quality and eight studies were of fair quality.

Conclusion: This is one of the first pooled meta-analysis studies on the role of miRNAs in the prognosis of melanoma. Our findings are inconclusive but suggest that miRNA expression could predict poor survival in melanoma patients. Therefore, miRNA expression could act as promising prognostic marker for melanoma.

Original languageEnglish
Pages (from-to)653-669
Number of pages17
JournalMolecular Diagnosis and Therapy
Volume22
Issue number6
Early online date27 Sep 2018
DOIs
Publication statusPublished - Dec 2018

Fingerprint

MicroRNAs
Meta-Analysis
Melanoma
Survival
Bibliographic Databases
Confidence Intervals
Publication Bias
Skin Neoplasms
Down-Regulation
Guidelines

Cite this

Sabarimurugan, S., Madurantakam Royam, M., Das, A., Das, S., Gothandam, G., & Jayaraj, R. (2018). Systematic Review and Meta-analysis of the Prognostic Significance of miRNAs in Melanoma Patients. Molecular Diagnosis and Therapy, 22(6), 653-669. https://doi.org/10.1007/s40291-018-0357-5
Sabarimurugan, Shanthi ; Madurantakam Royam, Madhav ; Das, Ankita ; Das, Shrestha ; Gothandam, G. ; Jayaraj, Rama. / Systematic Review and Meta-analysis of the Prognostic Significance of miRNAs in Melanoma Patients. In: Molecular Diagnosis and Therapy. 2018 ; Vol. 22, No. 6. pp. 653-669.
@article{2e851843088242e29c6b6362aa5afc46,
title = "Systematic Review and Meta-analysis of the Prognostic Significance of miRNAs in Melanoma Patients",
abstract = "Background: Melanoma is the most aggressive and deadly form of skin cancer. The molecular variability involving microRNA (miRNA) expression plays a significant role in melanogenesis, which leads to poor prognostic effects in melanoma. Since there is a scarcity of comprehensive data on the prognostic role of miRNAs in melanoma patients, this study focuses on filling this knowledge gap through a systematic review and meta-analysis. Methods: The included studies were extracted from several bibliographic databases between 2012 and 2018 using multiple keywords according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The hazard ratios (HRs) and 95{\%} confidence intervals (CIs) for different survival endpoints were compared to the high and low expression levels of miRNAs. The mean effect size of HR values was estimated using a random-effects model of meta-analysis. Inverted funnel plot symmetry was used to assess publication bias. Subgroup analysis was carried out individually for multiple miRNAs across different studies. Results: A total of 24 studies across eight countries were included, of which 16 studies were eligible for meta-analysis. Twenty-five miRNA expression levels were studied from 2669 melanoma patients to estimate the association between the prognostic role of miRNAs and survival outcome in these 16 studies. The overall pooled effect size (HR) for up- and downregulated miRNAs was 1.043 (95{\%} CI 0.921–1.181; p = 0.506), indicating that the miRNA expression increased the likelihood of death in melanoma patients by 4.3{\%}. Subgroup analysis for miRNA10b, miRNA16 and miRNA21 showed a poor prognosis. The quality assessment revealed that 16 studies were good quality and eight studies were of fair quality. Conclusion: This is one of the first pooled meta-analysis studies on the role of miRNAs in the prognosis of melanoma. Our findings are inconclusive but suggest that miRNA expression could predict poor survival in melanoma patients. Therefore, miRNA expression could act as promising prognostic marker for melanoma.",
author = "Shanthi Sabarimurugan and {Madurantakam Royam}, Madhav and Ankita Das and Shrestha Das and G. Gothandam and Rama Jayaraj",
year = "2018",
month = "12",
doi = "10.1007/s40291-018-0357-5",
language = "English",
volume = "22",
pages = "653--669",
journal = "Molecular Diagnosis and Therapy",
issn = "1084-8592",
publisher = "Adis International Ltd",
number = "6",

}

Sabarimurugan, S, Madurantakam Royam, M, Das, A, Das, S, Gothandam, G & Jayaraj, R 2018, 'Systematic Review and Meta-analysis of the Prognostic Significance of miRNAs in Melanoma Patients', Molecular Diagnosis and Therapy, vol. 22, no. 6, pp. 653-669. https://doi.org/10.1007/s40291-018-0357-5

Systematic Review and Meta-analysis of the Prognostic Significance of miRNAs in Melanoma Patients. / Sabarimurugan, Shanthi; Madurantakam Royam, Madhav; Das, Ankita; Das, Shrestha; Gothandam, G.; Jayaraj, Rama.

In: Molecular Diagnosis and Therapy, Vol. 22, No. 6, 12.2018, p. 653-669.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Systematic Review and Meta-analysis of the Prognostic Significance of miRNAs in Melanoma Patients

AU - Sabarimurugan, Shanthi

AU - Madurantakam Royam, Madhav

AU - Das, Ankita

AU - Das, Shrestha

AU - Gothandam, G.

AU - Jayaraj, Rama

PY - 2018/12

Y1 - 2018/12

N2 - Background: Melanoma is the most aggressive and deadly form of skin cancer. The molecular variability involving microRNA (miRNA) expression plays a significant role in melanogenesis, which leads to poor prognostic effects in melanoma. Since there is a scarcity of comprehensive data on the prognostic role of miRNAs in melanoma patients, this study focuses on filling this knowledge gap through a systematic review and meta-analysis. Methods: The included studies were extracted from several bibliographic databases between 2012 and 2018 using multiple keywords according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The hazard ratios (HRs) and 95% confidence intervals (CIs) for different survival endpoints were compared to the high and low expression levels of miRNAs. The mean effect size of HR values was estimated using a random-effects model of meta-analysis. Inverted funnel plot symmetry was used to assess publication bias. Subgroup analysis was carried out individually for multiple miRNAs across different studies. Results: A total of 24 studies across eight countries were included, of which 16 studies were eligible for meta-analysis. Twenty-five miRNA expression levels were studied from 2669 melanoma patients to estimate the association between the prognostic role of miRNAs and survival outcome in these 16 studies. The overall pooled effect size (HR) for up- and downregulated miRNAs was 1.043 (95% CI 0.921–1.181; p = 0.506), indicating that the miRNA expression increased the likelihood of death in melanoma patients by 4.3%. Subgroup analysis for miRNA10b, miRNA16 and miRNA21 showed a poor prognosis. The quality assessment revealed that 16 studies were good quality and eight studies were of fair quality. Conclusion: This is one of the first pooled meta-analysis studies on the role of miRNAs in the prognosis of melanoma. Our findings are inconclusive but suggest that miRNA expression could predict poor survival in melanoma patients. Therefore, miRNA expression could act as promising prognostic marker for melanoma.

AB - Background: Melanoma is the most aggressive and deadly form of skin cancer. The molecular variability involving microRNA (miRNA) expression plays a significant role in melanogenesis, which leads to poor prognostic effects in melanoma. Since there is a scarcity of comprehensive data on the prognostic role of miRNAs in melanoma patients, this study focuses on filling this knowledge gap through a systematic review and meta-analysis. Methods: The included studies were extracted from several bibliographic databases between 2012 and 2018 using multiple keywords according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The hazard ratios (HRs) and 95% confidence intervals (CIs) for different survival endpoints were compared to the high and low expression levels of miRNAs. The mean effect size of HR values was estimated using a random-effects model of meta-analysis. Inverted funnel plot symmetry was used to assess publication bias. Subgroup analysis was carried out individually for multiple miRNAs across different studies. Results: A total of 24 studies across eight countries were included, of which 16 studies were eligible for meta-analysis. Twenty-five miRNA expression levels were studied from 2669 melanoma patients to estimate the association between the prognostic role of miRNAs and survival outcome in these 16 studies. The overall pooled effect size (HR) for up- and downregulated miRNAs was 1.043 (95% CI 0.921–1.181; p = 0.506), indicating that the miRNA expression increased the likelihood of death in melanoma patients by 4.3%. Subgroup analysis for miRNA10b, miRNA16 and miRNA21 showed a poor prognosis. The quality assessment revealed that 16 studies were good quality and eight studies were of fair quality. Conclusion: This is one of the first pooled meta-analysis studies on the role of miRNAs in the prognosis of melanoma. Our findings are inconclusive but suggest that miRNA expression could predict poor survival in melanoma patients. Therefore, miRNA expression could act as promising prognostic marker for melanoma.

UR - http://www.scopus.com/inward/record.url?scp=85054195075&partnerID=8YFLogxK

U2 - 10.1007/s40291-018-0357-5

DO - 10.1007/s40291-018-0357-5

M3 - Review article

VL - 22

SP - 653

EP - 669

JO - Molecular Diagnosis and Therapy

JF - Molecular Diagnosis and Therapy

SN - 1084-8592

IS - 6

ER -